Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 1:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 104 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Radiation Therapy Standard of Care (SOC) Clear all
Completed Phase 3 Interventional

Immunotherapy Study for Surgically Resected Pancreatic Cancer

NCT01072981
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
HyperAcute-Pancreas Immunotherapy, Gemcitabine, 5FU Chemoradiation
Biological · Drug · Radiation
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
75
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 10, 2026, 1:33 PM EDT
Terminated Phase 2 Interventional Results available

Liver Directed RT + Chemo-immunotherapy for ES-SCLC

NCT04923776
View directory record Official record
Conditions
Small-cell Lung Cancer
Interventions
Carboplatin, Etoposide, Atezolizumab, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Brian Henick, MD
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Oct 10, 2026, 1:33 PM EDT
Terminated Phase 3 Interventional Results available

Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)

NCT02952586
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Avelumab, Chemoradiation
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
697 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
139
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 91 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 10, 2026, 1:33 PM EDT
Completed Not applicable Interventional

Randomized Evaluation of Machine Learning Assisted Radiation Treatment Planning vs Standard Radiation Treatment Planning

NCT05979883
View directory record Official record
Conditions
Cancer Head Neck, Cancer, Head, Cancer Neck
Interventions
Machine Learning Assisted Radiation (MLAP) RapidPlan, Radiation Therapy Standard of Care (SOC)
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 10, 2026, 1:33 PM EDT
Terminated Not applicable Interventional Results available

Commensal Oral Microbiota in Head and Neck Cancer

NCT03843554
View directory record Official record
Conditions
Head and Neck Cancer, Oral Mucositis
Interventions
Standard of Care Oral Hygiene, Oral mucosal deterging and dental prophylaxis
Other · Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 10, 2026, 1:33 PM EDT
Active, not recruiting Not applicable Interventional Results available

Lymphocyte Depletion and Change in Lymphocyte Functionality

NCT04273893
View directory record Official record
Conditions
Lymphocyte Depletion
Interventions
SBRT with additional treatment planning dose optimization, SBRT with standard of care planning only, Blood Draws
Radiation · Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 10, 2026, 1:33 PM EDT
Recruiting Phase 1 Interventional

An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast Cancer, The UTMOST2 Trial

NCT06999798
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma
Interventions
Diagnostic Mammography, Resection, Ultrasound Imaging, Twinkling Marker Placement
Procedure · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 10, 2026, 1:33 PM EDT
Recruiting Phase 3 Interventional

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

NCT07499674
View directory record Official record
Conditions
Lung Cancer, Lung Metastases
Interventions
Abenacianine, Near Infrared (NIR) Imaging
Drug · Other
Lead sponsor
Vergent Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Duarte, California • Newport Beach, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 10, 2026, 1:33 PM EDT
Terminated Phase 4 Interventional Results available

Intradiscal Platelet Rich Plasma

NCT04544709
View directory record Official record
Conditions
Discogenic Pain, Low Back Pain, Chronic Pain
Interventions
Low back intradiscal injection of platelet rich plasma (PRP)
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 10, 2026, 1:33 PM EDT
Completed Not applicable Interventional

A Survivorship Care Plan and Embedded Navigation Tool

NCT03424837
View directory record Official record
Conditions
Prostate Cancer
Interventions
ASCENT
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 10, 2026, 1:33 PM EDT
Not listed Not applicable Interventional

Validating Low FDG Dose PET/CT Compared to Current Standard of Care Dose PET/CT

NCT03519659
View directory record Official record
Conditions
PET/CT Imaging
Interventions
PET/CT scan with 13 mCi radiation dose, PET/CT scan with 5 mCi radiation dose, PET/CT scan with 2.5 mCi radiation dose, PET/CT Scan with 6.5 mCi radiation dose, PET/CT Scan with not yet determined radiation dose
Diagnostic Test
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 10, 2026, 1:33 PM EDT
Recruiting Phase 3 Interventional

Total RadIoTherapy of Oligometastatic caNcerS

NCT06587490
View directory record Official record
Conditions
Oligometastatic Malignant Solid Neoplasm
Interventions
stereotactic ablative radiotherapy
Radiation
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 10, 2026, 1:33 PM EDT
Recruiting Phase 2 Interventional

The University of Miami Adapt (UAdapt) Trial

NCT06111313
View directory record Official record
Conditions
Prostate Cancer
Interventions
FTLEAD, Ultra-Short-Term Androgen Deprivation Therapy with Relugolix, HypoLEAD, ADT Standard of Care
Radiation · Drug
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 85 Years · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 10, 2026, 1:33 PM EDT
Completed Phase 2 Interventional Results available

Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme

NCT00323115
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Autologous Dendritic Cell, Temozolomide, Radiotherapy, Dendritic Cell Vaccine
Biological · Drug · Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 10, 2026, 1:33 PM EDT
Recruiting Not applicable Interventional

Manual Lymphatic Drainage Breast Massage in Breast Cancer Patients After Breast Conserving Surgery

NCT06297265
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Localized Breast Carcinoma
Interventions
Lymphedema Management, Questionnaire Administration, Adjuvant breast radiation therapy
Other · Radiation
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 10, 2026, 1:33 PM EDT
Completed Not applicable Interventional Results available

Comparison of Glenoid Component Position Using Intelligent Reusable Instrument (IRI) vs Standard Surgical Instruments

NCT01801241
View directory record Official record
Conditions
Anatomic Total Shoulder Arthroplasty
Interventions
Anatomic TSA using IRI Instrumentation, Anatomic Total Shoulder Arthroplasty
Device · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 10, 2026, 1:33 PM EDT
Recruiting Phase 1Phase 2 Interventional

DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

NCT06504381
View directory record Official record
Conditions
High Grade Glioma, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma
Interventions
DB107-RRV, DB107-FC, Radiation Therapy (RT), Temozolomide, Magnetic Resonance Imaging (MRI), Surgical resection
Genetic · Drug · Radiation + 1 more
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2042
U.S. locations
5
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 10, 2026, 1:33 PM EDT
Completed Phase 3 Interventional Results available

Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)

NCT03830866
View directory record Official record
Conditions
Locally Advanced Cervical Cancer
Interventions
Durvalumab, Cisplatin, Carboplatin, external beam radiation therapy (EBRT) + brachytherapy
Biological · Drug · Radiation
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Phoenix, Arizona • La Jolla, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 10, 2026, 1:33 PM EDT
Active, not recruiting Phase 2 Interventional

Remote Cognitive Assessment and Wearable Device While Assessing the Impact of Metformin in Patients With History of Cranial Radiation Therapy

NCT06377696
View directory record Official record
Conditions
Malignant Brain Neoplasm
Interventions
Best Practice, Medical Device Usage and Evaluation, Metformin, Neurocognitive Assessment, Questionnaire Administration
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 10, 2026, 1:33 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers

NCT03515538
View directory record Official record
Conditions
Oral Mucositis
Interventions
RRx-001, Cisplatin for injection, Radiation Therapy
Drug · Radiation
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
12
States / cities
Santa Monica, California • Denver, Colorado • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 10, 2026, 1:33 PM EDT
Recruiting Phase 2 Interventional

Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)

NCT06912763
View directory record Official record
Conditions
Fibrosis Syndrome, Lymphedema, Head &Amp; Neck Cancer, Fibrosis
Interventions
Pravastatin (drug), Pentoxifylline, ketoprofen, Pirfenidoneone, Standard of Care (SOC), tocopherol
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 10, 2026, 1:33 PM EDT
Recruiting Early Phase 1 Interventional

Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer

NCT06914999
View directory record Official record
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Computed Tomography, Fludeoxyglucose F-18, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Positron Emission Tomography, Sodium Fluoride F-18
Procedure · Other · Radiation + 1 more
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 10, 2026, 1:33 PM EDT
Recruiting Phase 2 Interventional

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

NCT05681195
View directory record Official record
Conditions
Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, Relapsed Cancer, Refractory Cancer
Interventions
Pemetrexed, Zanubrutinib, Autologous Stem Cell Transplant (ASCT), Whole Brain Radiation Therapy (WBRT)
Drug · Procedure · Radiation
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 10, 2026, 1:33 PM EDT
Not yet recruiting Early Phase 1 Interventional

Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery

NCT07674771
View directory record Official record
Conditions
Prostate Cancer, Castration Sensitive Prostate Cancer, Metastatic Prostate Cancer, Adaptive Radiotherapy
Interventions
Drug: 68-Ga PSMA11, Adaptive stereotactic ablative radiotherapy (SABR), 68Ga-PSMA-11, Adaptive stereotactive ablative radiotherapy (SABR)
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 10, 2026, 1:33 PM EDT